Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
-885K
-
Total reported value, excl. options
-
$401M
-
Value change
-
-$37.6M
-
Put/Call ratio
-
0.93
-
Number of buys
-
88
-
Number of sells
-
-69
-
Price
-
$3.28
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2024
203 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q2 2024.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
.
Largest 10 shareholders include Redmile Group, LLC (13.2M shares), VANGUARD GROUP INC (10.6M shares), BlackRock Inc. (10.1M shares), Boxer Capital, LLC (8.22M shares), Deep Track Capital, LP (5.57M shares), STATE STREET CORP (5.34M shares), Bellevue Group AG (4.84M shares), CITADEL ADVISORS LLC (4.49M shares), D. E. Shaw & Co., Inc. (4.08M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.56M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.